PLEURAL MESOTHELIOMA: ETIOLOGY, INCIDENCE, DIAGNOSIS, TREATMENT AND SURVIVAL

PLEURAL MESOTHELIOMA: ETIOLOGY, INCIDENCE, DIAGNOSIS, TREATMENT AND SURVIVAL

The incidence rate of malignant pleural mesothelioma accounts for 0.2 cases per 100,000 population among men and 0.1 cases among women in Russia, and 0.88 and 0.67 cases respectively in Altai Territory. Recently, there has been a growing number of the incidences due to asbestos in the 70th years of the last century. Malignant mesothelioma is distinguished by a prolonged latency period, and constitutes a highly aggressive tumor.

By now, the diagnosis of pleural mesothelioma. CT and US-scans are used together with chest X-ray. Morphological confirmation of tumor (biopsy and cytologic examination of exudation complemented by immunocytochemical technique) is obligatory. Treatment of malignant mesothelioma mainly includes chemotherapy with cisplatin and pemetrexed. Radical surgery is more frequently impossible considering a diffusion growth of mesothelioma. Radiotherapy is used as prevention, and applied to a puncture point and post-surgery to prevent local recurrence.

The life expectancy of the patients with malignant pleural is poor: from 4 to 12 months with an average of 7 months. Only 26.5% of such patients have an expectancy greater than one year, and 6.8% of such patients live longer than 3 years. Maximum life expectancy of patients with malignant pleural mesothelioma accounts for 44 months. These are the women diagnosed in the left-sided pleural space with epithelioid mesothelioma.

The life expectancy of the patients with malignant pleural is poor: from 4 to 12 months with an average of 7 months. Only 26.5% of such patients have an expectancy greater than one year, and 6.8% of such patients live longer than 3 years. Maximum life expectancy of patients with malignant pleural mesothelioma accounts for 44 months. These are the women diagnosed in the left-sided pleural space with epithelioid mesothelioma.

The life expectancy of the patients with malignant pleural is poor: from 4 to 12 months with an average of 7 months. Only 26.5% of such patients have an expectancy greater than one year, and 6.8% of such patients live longer than 3 years. Maximum life expectancy of patients with malignant pleural mesothelioma accounts for 44 months. These are the women diagnosed in the left-sided pleural space with epithelioid mesothelioma.